Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL

EP: 1.Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024

EP: 2.Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

EP: 3.Application of Real-World Evidence in Selecting CAR T in R/R MM

EP: 4.Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

EP: 5.Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM

EP: 6.Future of Bispecifics and CAR T in R/R MM

Now Viewing

EP: 7.Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL

EP: 8.Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial

EP: 9.Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

EP: 10.Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

EP: 11.Implications of BTK Inhibitors Combined With CAR-T in R/R CLL/SLL

EP: 12.Overview of ZUMA-2 Cohorts 1-3: Use of Brexu-cel in R/R MCL

EP: 13.Insights From Augmented Hyper-CVAD (AHCVAD), a Pediatric-Inspired Regimen for Adults Younger Than 50 Years With ALL

EP: 14.Key Takeaways From ASH 2024

EP: 15.Looking Into the Future of AML Treatments

EP: 16.Looking Ahead For the Treatments of R/R MM

EP: 17.Recommendations For Future Clinical Trials in R/R MM

EP: 18.Treatment and Management of MM with Amyloidosis

EP: 19.Highlighting the Key Takeaways From ASH 2024

Video content above is prompted by the following:

ZUMA-5 5-Year Follow-Up: Axicabtagene Ciloleucel in R/R iNHL

Key Findings

Long-Term Efficacy Highlights

• Sustained durable responses observed in patients with R/R iNHL
• Demonstrates the potential of CAR T-cell therapy as a transformative treatment approach
• Continued efficacy and manageable long-term safety profile beyond initial clinical trial period

Durability of Response

• Maintained complete response rates at 5 years
• Consistent progression-free survival in heavily pretreated patient population
• Suggests CAR T-cell therapy can provide long-term disease control in challenging iNHL cases

Clinical Implications

Treatment Strategy Considerations

• CAR T-cell therapy emerges as a potentially curative option for patients with multiple prior lines of therapy.
• Particularly promising for patients with limited treatment alternatives
• Supports earlier consideration of CAR T-cell therapy in the treatment algorithm for R/R iNHL

Patient Selection

• Most beneficial for patients with:
• Multiple prior treatment lines

• Chemotherapy-resistant disease

• Good performance status

• No significant comorbidities limiting CAR T-cell therapy eligibility

Practical Takeaways

• Long-term data reinforce the potential of axicabtagene ciloleucel as a meaningful treatment option.
• Encourages more aggressive consideration of CAR T-cell therapy earlier in the treatment paradigm
• Highlights the importance of comprehensive patient evaluation for CAR T-cell therapy candidacy

Recommendations

• Review individual patient characteristics carefully.
• Consider CAR T-cell therapy as a potential salvage or bridge to subsequent therapies.
• Discuss potential benefits and risks with patients, emphasizing long-term response potential.
• Integrate molecular and clinical factors in treatment decision-making.